



**Aktis Oncology** Priced, Nasdaq: AKTS  
Phase 1 biotech developing targeted radiopharmaceuticals to treat solid tumors.  
Industry: Health Care

Latest Trade: \$18.00 0.00 (0.0%)  
First Day Return: n/a  
Return from IPO: n/a



We are a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The field of targeted radiopharmaceuticals is currently led by two marketed products that illustrated transformative survival outcomes and quality of life benefits can be conferred by delivering radioisotopes to solid tumors. These leading products, which target prostate specific membrane antigen or somatostatin-2 receptor, are each currently approved in only one tumor type yet have seen considerable commercial uptake and have become fundamental pillars of cancer treatment. Despite these advances, we believe that the field of radiopharmaceuticals is still in its infancy, with many emerging companies still primarily focused on these same two targets. In contrast, we see a significant opportunity to broaden the cancer patient populations benefiting from targeted radiopharmaceuticals by developing next-generation technologies that expand the scope of tumor targets for which it is possible to safely deliver a powerful payload of an alpha-emitting radioisotope.

**IPO News** for Aktis Oncology

- Phase 1 solid tumor biotech Aktis Oncology prices IPO at \$18, the high end of the range 01/08/26
  - Aktis Oncology increases proposed IPO deal size by 50% to \$300 million, adding a \$100 million commitment from partner Eli Lilly 01/07/26
  - Phase 1 solid tumor biotech Aktis Oncology sets terms for \$200 million IPO; expected to trade on Friday 1/9 in first sizable IPO of 2... 01/05/26
- [more](#)

**IPO Data**

IPO Date	01/08/2026
Offer Price	\$18.00
Price Range	\$16.00 - \$18.00
Offer Shares (mm)	17.7
Deal Size (\$mm)	\$318
Lock-Up Date	IPO Pro Only
Street Research	IPO Pro Only

**Underwriters**

J.P. Morgan  
BofA Securities  
Leerink Partners  
TD Cowen  
[less](#)

**Company Data**

Headquarters	Boston, MA, United States
Founded	2020
Employees at IPO	76
Website	<a href="http://www.aktisoncology.com">www.aktisoncology.com</a>

**Aktis Oncology (AKTS) Performance**

AKTS vs. IPO Index (IPOUSA)

